Chemomab appoints Donald Marvin as CFO & COO, replacing Sigal Fattal effective Nov 8, 2021

Chemomab Therapeutics Ltd.

Sigal Fattal's engagement as interim CFO concluded by mutual agreement; she remains as senior consultant.
Donald Marvin named CFO, EVP & COO; base salary $460K, annual bonus target 45% of base.
Marvin receives 1.5% equity (4-yr vest) + up to 0.5% for strategic goals, $25K signing bonus.
Severance package of 12 months, increasing by 1 month every 2 years (max 18 months).
Marvin brings 35+ years experience; no family relationships or reportable transactions.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Donald Marvin

Chief Financial Officer, Executive Vice President and Chief Operating Officer

CMMB · Chemomab Therapeutics Ltd.

Effective: 2021-11-08
Filed: November 12, 2021, 6:59 PM ET

it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Donald Marvin was appointed as Chief Financial Officer, Executive Vice President and Chief Operating Officer at Chemomab Therapeutics Ltd..

Action: appointed
Role: Chief Financial Officer, Executive Vice President and Chief Operating Officer

Exact text from the filing

it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.

View on SEC.gov

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-21-003512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.